Recently, the 2025 Deloitte China Technology Fast Program Award Ceremony was successfully held in Wuxi, China. After a three-month selection process, Dermavon, the skin health business company of CMS, was included in the list of “Deloitte China LSHC Rising Star” by virtue of its leading innovative product layout in the skin health field, as well as its promising growth and development potential.
The theme of this year’s “Technology Fast Program” selection is “Boundless Innovation, Resilient Growth”. Through the review by the Professional Committee, enterprise presentation and scoring, and other processes, the selection comprehensively evaluates enterprise valuation, technological innovation, market prospects, industry ranking, etc., and selects excellent enterprises with both innovation capabilities and growth potential, so as to encourage enterprises to break through technological boundaries and promote the continuous construction of the innovation ecosystem. Being selected into this list is a full recognition of Dermavon’s leading industry position, comprehensive and differentiated innovative product portfolio, and high-growth prospects.
Since its independent operation in 2021, Dermavon has developed into China’s leading innovative pharmaceutical company specialized in skin health, with unified operations combining the R&D, production, and sales of dermatological prescription products and dermatology-grade skincare products. It is committed to providing comprehensive skin health solutions, from prevention to treatment and long-term care. In the rapidly developing skin health field, Dermavon integrates collaborative R&D and in-house R&D to continuously improve its differentiated innovative product portfolio. Committing to innovation, Dermavon strives to create the Chinese standards for skin health and lead the continuous innovation of treatment and care solutions.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.